BR112022026094A2 - Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit - Google Patents

Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit

Info

Publication number
BR112022026094A2
BR112022026094A2 BR112022026094A BR112022026094A BR112022026094A2 BR 112022026094 A2 BR112022026094 A2 BR 112022026094A2 BR 112022026094 A BR112022026094 A BR 112022026094A BR 112022026094 A BR112022026094 A BR 112022026094A BR 112022026094 A2 BR112022026094 A2 BR 112022026094A2
Authority
BR
Brazil
Prior art keywords
hif
inhibitor
pharmaceutically acceptable
acceptable salt
lenvatinib
Prior art date
Application number
BR112022026094A
Other languages
English (en)
Portuguese (pt)
Inventor
Fleury PERINI Rodolfo
M Pinheiro Elaine
Willemann Rogerio Jaqueline
Original Assignee
Merck Sharp & Dohme Llc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc, Eisai R&D Man Co Ltd filed Critical Merck Sharp & Dohme Llc
Publication of BR112022026094A2 publication Critical patent/BR112022026094A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112022026094A 2020-06-22 2021-06-21 Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit BR112022026094A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042307P 2020-06-22 2020-06-22
US202163146915P 2021-02-08 2021-02-08
PCT/US2021/038172 WO2021262563A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Publications (1)

Publication Number Publication Date
BR112022026094A2 true BR112022026094A2 (pt) 2023-01-17

Family

ID=79281740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026094A BR112022026094A2 (pt) 2020-06-22 2021-06-21 Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit

Country Status (10)

Country Link
US (1) US20230210838A1 (https=)
EP (1) EP4168008B1 (https=)
JP (1) JP7750884B2 (https=)
KR (1) KR20230026493A (https=)
CN (1) CN115803629A (https=)
AU (1) AU2021296151A1 (https=)
BR (1) BR112022026094A2 (https=)
CA (1) CA3183852A1 (https=)
MX (2) MX2022016406A (https=)
WO (1) WO2021262563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
CN119731864A (zh) 2023-02-28 2025-03-28 株式会社Lg新能源 电化学装置用分隔件和包括其的电化学装置
AU2024248799A1 (en) * 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168510A1 (en) * 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
WO2020081695A1 (en) * 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Also Published As

Publication number Publication date
EP4168008A1 (en) 2023-04-26
JP7750884B2 (ja) 2025-10-07
JP2023531675A (ja) 2023-07-25
MX2025014865A (es) 2026-01-07
US20230210838A1 (en) 2023-07-06
EP4168008B1 (en) 2026-03-18
MX2022016406A (es) 2023-01-30
CN115803629A (zh) 2023-03-14
CA3183852A1 (en) 2021-12-30
EP4168008A4 (en) 2024-08-07
WO2021262563A1 (en) 2021-12-30
AU2021296151A1 (en) 2023-02-02
KR20230026493A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
MX2023014405A (es) Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii.
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
BR112022026094A2 (pt) Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit
CR20250458A (es) Composiciones para inducir la hidrólisis de ras gtp y sus usos
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
ZA202304965B (en) Combination therapy for treating cancer
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
Bokobza et al. Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
MX2025014866A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
MX2019003751A (es) Proteina terapeutica.
MX2021001764A (es) Terapia de combinacion.
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.